drugset

drugset / Trial / NCT00163085

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

NCT00163085 ↗

Phase 2 Completed 12 enrolled Pfizer

RandomizedCrossoverDouble-blindTreatment

Summary

To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease

Timeline

Start: 2005-05
Primary completion: —
Completion: 2006-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CP-101,606	Unknown	—	—

Indications